Stereoelectronic properties of spiroquinazolinones in differential PDE7 inhibitory activity
暂无分享,去创建一个
[1] K. Chung,et al. Phosphodiesterase inhibitors in airways disease , 2006 .
[2] A. Becke. A New Mixing of Hartree-Fock and Local Density-Functional Theories , 1993 .
[3] H. Ke,et al. Multiple Elements Jointly Determine Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases 4 and 7* , 2005, Journal of Biological Chemistry.
[4] H. Dyke,et al. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. , 2001, Bioorganic & medicinal chemistry letters.
[5] Y. Martin,et al. Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.
[6] J. Karle,et al. Stereoelectronic properties of antimalarial artemisinin analogues in relation to neurotoxicity. , 1999, Chemical research in toxicology.
[7] A. Karpfen,et al. Molecular Geometries and Vibrational Spectra of Phenol, Benzaldehyde, and Salicylaldehyde: Experimental versus Quantum Chemical Data , 1997 .
[8] Electrostatics in chemistry , 1999 .
[9] Thomas Lengauer,et al. A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.
[10] Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors , 2005, Medicinal research reviews.
[11] J. Palacios,et al. Differential distribution of cAMP‐specific phosphodiesterase 7A mRNA in rat brain and peripheral organs , 2001, Synapse.
[12] P. Berna,et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives. , 2004, Bioorganic & medicinal chemistry letters.
[13] J. Y. Roberge,et al. Identification of purine inhibitors of phosphodiesterase 7 (PDE7). , 2004, Bioorganic & medicinal chemistry letters.
[14] P. Soulard,et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. , 2004, Bioorganic & medicinal chemistry letters.
[15] É. Chevalier,et al. PDE7 Inhibitors: Chemistry and Potential Therapeutic Utilites , 2005 .
[16] Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[17] T. Halgren. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions , 1996 .
[18] Parr,et al. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. , 1988, Physical review. B, Condensed matter.
[19] M. Pruniaux,et al. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. , 2007, Pulmonary pharmacology & therapeutics.
[20] D. Underwood,et al. Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents. , 2003, Journal of medicinal chemistry.
[21] F. J. Luque,et al. Generalization of the Molecular Electrostatic Potential for the Study of Noncovalent interactions , 1996 .
[22] Thomas A. Halgren,et al. Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94 , 1996, J. Comput. Chem..
[23] David G. Brown,et al. Design of second generation phosphodiesterase 5 inhibitors. , 2007, Current topics in medicinal chemistry.
[24] T. Halgren. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular‐interaction energies and geometries , 1999, Journal of computational chemistry.
[25] T. Halgren. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..
[26] J. Murray,et al. Molecular electrostatic potentials : concepts and applications , 1996 .
[27] Susan J. Smith,et al. Phosphodiesterase 7 (PDE7) as a therapeutic target , 2006 .
[28] R. Cantor,et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response , 2006, Proceedings of the National Academy of Sciences.
[29] K. Wanner,et al. Methods and Principles in Medicinal Chemistry , 2007 .
[30] B. Pullman,et al. Molecular electrostatic potential of the nucleic acids , 1981, Quarterly Reviews of Biophysics.
[31] David T Manallack,et al. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. , 2005, Journal of medicinal chemistry.
[32] Adriaan P. IJzerman,et al. Relative binding orientations of adenosine A1 receptor ligands — A test case for Distributed Multipole Analysis in medicinal chemistry , 1995, J. Comput. Aided Mol. Des..
[33] Kam Y. J. Zhang,et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. , 2004, Molecular cell.
[34] A. Becke. Density-functional thermochemistry. III. The role of exact exchange , 1993 .
[35] F. Menniti,et al. Phosphodiesterases in the CNS: targets for drug development , 2006, Nature Reviews Drug Discovery.
[36] J. Karle,et al. Molecular electronic properties of a series of 4-quinolinecarbinolamines define antimalarial activity profile. , 1996, Journal of medicinal chemistry.
[37] T. Sasaki,et al. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors , 2002, Clinical and experimental immunology.
[38] Maria Kontoyianni,et al. Evaluation of docking performance: comparative data on docking algorithms. , 2004, Journal of medicinal chemistry.
[39] S. Sj,et al. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? , 2006 .
[40] P. Berna,et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives. , 2004, Bioorganic & medicinal chemistry letters.
[41] Anthony K. Grafton,et al. A COMPARISON OF THE PROPERTIES OF VARIOUS FUSED-RING QUINONES AND THEIR RADICAL ANIONS USING HARTREE-FOCK AND HYBRID HARTREE-FOCK/DENSITY FUNCTIONAL M ETHODS , 1997 .
[42] Steven D. Schwartz,et al. Molecular Electrostatic Potential Analysis for Enzymatic Substrates, Competitive Inhibitors, and Transition-State Inhibitors , 1996 .
[43] Didier Rognan,et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.
[44] Y. Jeon,et al. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development , 2005, Cellular and Molecular Life Sciences CMLS.
[45] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[46] T. K. Chandrashekar,et al. 22pi smaragdyrin molecular conjugates with aromatic phenylacetylenes and ferrocenes: Syntheses, electrochemical, and photonic properties. , 2006, Journal of the American Chemical Society.
[47] Y. Shimizu,et al. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. , 2007, European journal of pharmacology.
[48] J. Beavo,et al. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.